Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012181 · ClinicalTrials.gov registry record · Phase 1
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00012181: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00012181 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00012181, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.
Interventions
- OTHER pharmacological study
- DRUG alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012181
The ClinicalTrials.gov registry entry for NCT00012181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00012181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012181 about?
NCT00012181 is a clinical study titled "Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas". Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.
What is the current status of trial NCT00012181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2001-04.
What interventions are being tested in trial NCT00012181?
The interventions under investigation include: pharmacological study (OTHER), alvocidib (DRUG).
Who is sponsoring clinical trial NCT00012181?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.